Contralateral tissue sparing in lymph node-positive breast cancer radiotherapy with VMAT technique.

The objective of this study was to modify volumetric modulated arc therapy (VMAT) design for breast irradiation with axillary lymph node involvement to enhance normal tissue sparing while maintaining good planning target volume (PTV) coverage. Four VMAT plans were generated retrospectively for 10 patients with breast cancer for comparison. First, 2 partial arcs with an avoidance sector (Pavoid) for the lung and the heart were created. Second, a split-arc design with 2 partial arcs was used, changing the collimator angle by splitting the arcs in the middle, resulting in 4 partial arcs (Psplit). Third, the arc angles in the Psplit were modified to emphasize tangential directions, corresponding to the avoidance sector in Pavoid, resulting in 2 lateral and 2 anterior partial arcs. Furthermore, a fifth arc was added to ensure the coverage of axillary lymph nodes (Ptang). Fourth, one of the anterior arcs was removed to limit the number of arcs during treatment (Ptang-1). PTV coverage was the highest in Psplit with a V90%(PTV) of 98.4 ± 0.6%. Also the dose homogeneity and conformity were the best (p < 0.02) in Psplit, and a smaller high-dose volume was distributed to the ipsilateral lung, heart, and humeral head, than in the other designs. In Ptang and Ptang-1, the PTV coverage was acceptable with V90%(PTV) of 97.9 ± 0.8% and 98.0 ± 0.8%, respectively, and low-dose volumes in normal tissue were smaller compared with Psplit. The removal of 1 partial arc from Ptang (Ptang-1) did not have a significant effect on dose parameters. In Pavoid, the contralateral breast and lung volumes of low-dose level were the smallest. However, the PTV coverage was reduced (V90% = 97.0 ± 1.6%), and the heart, ipsilateral lung, and humeral head received significantly higher doses than in other designs. The modified split-arc methods Ptang and Ptang-1, emphasizing tangential directions, were close to the original split-arc method in PTV coverage while reducing the dose to the healthy tissues distant from the PTV. Ptang-1 is seen as a favorable treatment option over Ptang with less treatment time.
(Copyright © 2018 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.)